Replies to post #309408 on Amarin Corp Plc (AMRN)

[HinduKush]

Iryo
You may well be right...this is why a head to head in vivo PK and EPA level study is urgently needed once Amrn gets hold of this HIKMA generic V--all the more so because R-IT outcomes and plaque regression are correlated with EPA levels and it is the EPA which is the magic sauce.
AHA 2020
“Achieved Eicosapentaenoic Acid (EPA) Levels Predicts Regression of Coronary Plaque Volumes by Coronary Computed Tomography Angiography (CCTA) in the EVAPORATE Trial” – presented on behalf of all authors by Suvasini Lakshmanan
“Eicosapentaenoic Acid, but Not Docosahexaenoic Acid or a Mixed Omega-3 Fatty Acid Supplement, Inhibits Low-density Lipoprotein Oxidation in a Time-dependent Manner”
HK